SuperworthAchieve Life Sciences ACHV
- Market cap
- $667.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Achieve Life Sciences' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $3.6M−64% | $2.1M−76% | $2.8M−49% | $5.1M+12% | $7.6M+113% | $7.3M+245% | $7.1M+154% | $6.7M+31% | $5.3M−30% | n/a | n/a | n/a |
| SG&A | $3M+8% | $2.3M+1% | $3.2M+5% | $3.3M+6% | $4.9M+62% | $4.9M+115% | $5.8M+82% | $5.9M+77% | $9.4M+93% | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Interest expense | $781K+62% | $787K+44% | $813K+42% | $804K+13% | $366K−53% | $197K−75% | $185K−77% | $191K−76% | $192K−48% | $251K+27% | $274K+48% | $277K+45% |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$7.1M−46% | −$5.5M−51% | −$6.5M−28% | −$8.5M+3% | −$12.5M+76% | −$12.4M+126% | −$12.8M+98% | −$12.7M+50% | −$14.4M+15% | −$14.7M+19% | −$10.2M−21% | −$74.8M+488% |
| −$0.34−75% | −$0.26−69% | −$0.26−48% | −$0.25−42% | −$0.36+6% | −$0.36+39% | −$0.37+42% | −$0.37+48% | −$0.28−22% | −$0.27−25% | −$0.19−49% | −$0.80+116% | |
| 21.1M+118% | 21.2M+56% | 25M+40% | 34.3M+80% | 34.4M+63% | 34.5M+63% | 34.7M+39% | 34.7M+1% | 51M+49% | 53.7M+56% | 53.4M+54% | 93.5M+170% |
Operating income: Q4 FY10 and Q4 FY11: not printed by the filing, worked out from its own lines.
Net income: Q4 FY10: not printed by the filing, worked out from its own lines.
EPS, diluted: 10 periods, Q2 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 15 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Achieve Life Sciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ACHVAchieve Life Sciences | $667.8M | n/m | n/a | n/m | n/m | n/m | |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| CDNACareDx | $3.6B | 33.4× | 19.1× | 7.8× | +34% | 24.2% | |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | 6.9× | +17% | 20.4% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| BLLNBillionToOne | $5.1B | 166× | 151× | 12.8× | +90% | 9.5% | |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | 4.2× | +2% | 17.7% | |
| Peer median | $3.7B | 61.0× | 39.6× | 5.5× | +13% | 13.6% |
More on Achieve Life Sciences
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .